Unituxin Intravenous Infusion 17.5mg / 5mL specific drug use-results survey (Survey of all cases)

Post-marketing observational study of Unitaxin IV infusion 17.5 mg / 5 mL in Japanese patients with neuroblastoma after high-dose chemotherapy - Unituxin--J-PMS

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031210508

Enrollment

120

Registered

2021-12-23

Start date

2021-12-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroblastoma after high-dose chemotherapy Unituxin, neuroblastoma, after high-dose chemotherapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients receiving Unituxin after September 22, 2021 Patients with neuroblastoma after high-dose chemotherapy

Exclusion criteria

Exclusion criteria: Patients with a history of hypersensitivity to the ingredients of Unituxin

Design outcomes

Primary

Measure	Time frame
Safety prefecture side effect incidence rate Prognosis survey Overall survival rate at 5 years, Information about growth and developmental disorders, Presence or absence of safety considerations	—

Secondary

Measure	Time frame
best overall response	—

Contacts

Public ContactPMS unit Medicine Development Center

OHARA Pharmaceutical Co., Ltd.

pms-md@ohara-ch.co.jp+81-3-6740-7701

Outcome results